|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?|
|Jung Hwan Yu, Jin-Woo Lee|
P1218 STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 3 DOESN'T AFFECT THE OUTCOME OF PEGINTERFERON ALPHA-2a PLUS RIBAVIRIN TREATMENT
Adipokines, insulin resistance, hepatic steatosis, and necroinflammation in patients with chronic viral hepatitis
P1-124: Does hepatic involvement affect outcome in dengue Infection?
1120 ALTERED SERUM ADIPOCYTOKINES LEVELS DO AFFECT HEPATIC STEATOSIS AND FIBROSIS IN CHRONIC HEPATITIS B AND CHRONIC HEPATITIS C INDIAN PATIENTS
Altered Serum Adipocytokines Levels Do Affect Hepatic Steatosis and Fibrosis in Chronic Hepatitis B and Chronic Hepatitis C Indian Patients
Chronic urinary retention in men: How we define it, and how does it affect treatment outcome
Does the presence of hepatic steatosis influence the efficacy of antiviral treatment in patients with hepatitis C?
Hepatic steatosis — a sign of severity in the evolution of HCV chronic hepatitis?
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks
Hepatic steatosis in patients with chronic hepatitis C virus infection
|This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.|